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BREAST CANCER AND SEXUAL HEALTH:  
THE IMPACT OF TREATMENT ON SEXUAL LIFE, SELF-CONCEPT, 
RELATIONSHIPS, AND THE INTIMATE PARTNER  
 
NICOLINA S. MASCIA  
ABSTRACT 
 
As breast cancer survival rates increase, quality of life issues should be addressed, 
specifically regarding sexual health. Breast cancer treatment can lead to sexual 
dysfunction, alterations in self-concept, body image, self-esteem, and relationship issues 
which can cause a depressed quality of life. These sexual health issues can also uniquely 
affect the intimate partner. It appears that a strong relationship and supportive intimate 
partner can protect against the stressors due to these sexual problems. Addressing sexual 
concerns, whether physical, psychological, or relational are a clear necessity in managing 
the care of patients with breast cancer, regardless of partner status, age, or disease stage. 
Clinicians and medical professionals should address these issues in patient care plans, 
examinations, and patient education, focusing not only on the patient but also on the 
couple as a unit. However, there are barriers to communication in regards to sexuality on 
both the part of the physician and the patient that cause a discrepancy between available 
resources and patients actually receiving those resources. Developing effective treatment 
plans and interventions are essential in improving the quality of life in women suffering 
from physical, psychological, and relational sexual issues due to the management of 
breast cancer.  
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INTRODUCTION 
 
 Breast cancer (BC) is the most common malignancy affecting women within the 
United States (“WHO | Breast cancer,” n.d.). The incidence of breast cancer in the 
developing world is increasing due to the increase in life expectancy, urbanization, and 
adoption of western ways of life (“WHO | Breast cancer,” n.d.). Fortunately, more 
women are surviving their diagnosis, and breast cancer survivors make up 41% of the 
entire population of cancer survivors (Candy, Jones, Vickerstaff, Tookman, & King, 
2016). With a diagnosis of breast cancer comes a multitude of physical and psychological 
consequences, often the greatest of these challenges are related to sexual function and 
sexual self-concept. In a survey conducted by the LiveStrong Foundation in 2010, (24% 
of the reporting population had breast cancer), sexual functioning and satisfaction were 
ranked the third most frequently reported concern (“Challenges Reported by Post-
Treatment Cancer Survivors in the LIVESTRONG Surveys | What We Do | 
LIVESTRONG.org,” n.d.).  Diagnosis and especially treatment for most cancers can 
causes issues with sexual function (Sadovsky et al., 2010). However, breast cancer raises 
specific concerns due to the breasts’ role in feminine sexuality and role as a source of 
sexual stimulation, eroticism, and pleasure. 
Sexual health goes beyond the idea of arousal and orgasm. There are multiple 
facets of sexual health, including desire, sensuality, arousal, orgasm, satisfaction, pain, 
and lubrication (Boswell & Dizon, 2015). There are also multiple contributing factors, 
such as partner status, overall health, body image, psychological health, comorbidities, 
and intimacy (Boswell & Dizon, 2015). The Diagnostic and Statistical Manual (5th 
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edition) now identifies dysfunction in sexual health as having three separate, but often 
interrelated parts: disorders of sexual interest and arousal, difficulty with orgasm, and 
disorders associated with genito-pelvic pain/penetration (American Psychiatric 
Association, 2013). One study of 83 breast cancer survivors using the Female Sexual 
Function Index (FSFI) found that 77% of the subjects qualified for the diagnosis of 
sexual dysfunction (Maiorino, Chiodini, Bellastella, Giugliano, & Esposito, 2015). 
Common cancer therapies (chemotherapy, endocrine therapy, surgeries, radiation) can 
cause changes to a woman’s sexual health and function, resulting in significant 
alterations in emotional stress (including depression), depressed self-confidence, and 
negative impacts on personal relationships, most specifically with one’s sexual partner. 
Sexuality and intimacy has been found to lessen emotional stress and improve the 
psychosocial response to a cancer diagnosis (Wimberly, Carver, Laurenceau, Harris, & 
Antoni, 2005). Therefore, it is important to examine the impact of breast cancer treatment 
on sexual dysfunction and sexual life. Finding the impact of breast cancer treatment on 
sexual dysfunction, sexual identity, and intimate relationships is crucial for developing 
effective interventions in order to improve the dysfunctions themselves, self-concept, 
relationships, and the overall quality of life for women with breast cancer and survivors.  
It is an exciting time in history as medicine slowly shifts toward a more whole-
person approach. With this shift, it is important to recognize the unique psychosocial 
changes that come with a breast cancer diagnosis and survivorship. There is a long-
standing principle that survival supersedes sexuality, but there is a significant 
diminishment in quality of life after breast cancer that could lead to sexual dysfunction 
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and altered sexual self-concept, the concept of self that is formed from one’s own beliefs 
and the response of others, and self-esteem. In addition, there is a misconception that 
because women with breast cancer and survivors are typically past middle age, perhaps 
into menopause, they are no longer interested in sexuality or intimacy. There is also 
evidence that sexual intimacy has been found to make the experience of cancer more 
manageable and to assist in the recovery process (Ussher, Perz, & Gilbert, 2012). 
Therefore, issues with sexual health and identity should be considered as part of the 
recovery process for breast cancer and should be more openly talked about among 
patients, clinicians, survivors, and the general public. However, this is not always the 
case. While there is an availability for treatments (whether effective or not) for sexual 
dysfunctions and identity issues, there is a huge discrepancy between self-reported need 
for professional help and actually receiving the care (Kedde, van de Wiel, Weijmar 
Schultz, & Wijsen, 2013). This could be due to a variety of factors. Health care 
professionals do not often bring up sexual problems due to time constraints, 
embarrassment, lack of knowledge on topics, lack of experience, and the inability to 
provide support (Kedde et al., 2013). It is likewise challenging for patients to mention 
these topics, perhaps feeling uncomfortable, embarrassed, or fearing judgment.  Of more 
concern, Wilmoth conducted a study of women of an average 50.5 years old with breast 
cancer and found that women who sought information about the sexual side effects of 
breast cancer treatment had a more successful adjustment to therapy-related changes 
(Wilmoth, 2001).  
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 The effects of breast cancer on sexuality are not usually discussed by clinicians, in 
patient’s care plans, or in patient education. Perhaps this is because sexuality is different 
for each individual person. Sexuality and sexual expression can be significant for breast 
cancer patients and their partners as the disease not only causes serious distress and fears 
but also affects body image, self-esteem, and the ability to express one’s sexuality. 
Sexual experiences and intimacy can then be sidelined during a time when those acts 
could be beneficial.  
This paper focuses on the impact of breast cancer treatment on sexual life with an 
emphasis on how the partner and couple’s relationship are affected. There is a lack of 
research on the intimate experiences of survivorship for the survivor and the intimate 
partner, post-treatment. This might be due to difficulty identifying participants willing to 
share their intimate experiences or to the perception that the breast cancer survivor is the 
only person in the couple impacted by this life-altering illness. Women who have 
undergone breast cancer treatment can experience sexual problems in the physical 
domain, psychological domain, and interpersonal domain. Their partner also has difficult 
experiences unique to their role. Therefore, there are a lot of factors at play in the 
intimate relationship. However, there is evidence that sexual intimacy can make the 
experience of cancer more manageable and to aide in recovery (Ussher et al., 2012). This 
paper suggests that a supportive intimate partner and strong partner relationship, even in 
the absence of sexual activity, can alleviate some of the distress caused by sexual 
dysfunction and the corresponding psychological and interpersonal problems. Perhaps, if 
there is a stable partner relationship, one is able to better battle breast cancer treatment’s 
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sexual side effects. The patient interviews in the final section of this paper show two 
survivors sharing a great deal of information regarding their unique struggle with breast 
cancer, their intimate relationship, and how they were able to live beyond breast cancer.  
 
Breast Cancer Statistics and Risk Factors 
 Breast cancer is the most common cancer among US women, excluding skin 
cancers, making up 29% of the newly diagnosed cancer cases (American Cancer Society, 
2015). A woman in the US has a 1 in 8 lifetime risk of being diagnosed with breast 
cancer (American Cancer Society, 2015). From 2008-2012, the median age of breast 
cancer diagnosis was 61, however premenopausal women are diagnosed as well 
(American Cancer Society, 2015). In 2015, it was estimated that 1, 650 women under 40 
were diagnosed with in situ cases, while 10, 500 of that same under 40 group were 
diagnosed with invasive cases (American Cancer Society, 2015). That same year, in the 
40-49 age category, there were an estimated 12, 310 in situ cases and 35, 850 invasive 
cases (American Cancer Society, 2015). For all age groups, there were an estimated 60, 
290 in situ cases, 231, 840 invasive cases, and 40, 290 deaths due to breast cancer 
(American Cancer Society, 2015). These staggering numbers show just how large a 
problem breast cancer is. Fortunately, however, the mortality rates are decreasing 
(American Cancer Society, 2015).  
Several risk factors are well documented (see Table 1). Familial history increases 
the relative risk by a factor of two or three (“WHO | Breast cancer,” n.d.). Mutations in 
genes such as BRCA1, BRCA2, and p53 confer very high risks of breast cancer, but are 
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rare and account for a small portion of the total breast cancer population (“WHO | Breast 
cancer,” n.d.).  
 Reproductive factors associated with prolonged exposure to endogenous estrogens 
(such as early menarche, late menopause, late age at first childbirth) are some of the most 
crucial risk factors (“WHO | Breast cancer,” n.d.). Exogenous hormones, oral 
contraceptives, and hormone replacement therapy users are at a higher risk than non-
users (“WHO | Breast cancer,” n.d.). Breastfeeding appears to be a protective factor 
(Lacey et al., 2009).  
Table 1. Factors that increase relative risk for breast cancer in women  
Relative Risk  Factor 
>4.0 !! Age (65+ vs <65) 
!! Biopsy-confirmed atypical 
hyperplasia 
!! BRCA1 and/or BRCA2 gene 
!! Ductal carcinoma in situ 
!! Lobular carcinoma in situ 
!! Personal history of early-onset 
(<40 years) BC 
!! Two or more first-degree relatives 
with BC diagnosed at an early age 
2.1-4.0 !! High endogenous estrogen or 
testosterone levels 
!! High-dose radiation to chest 
!! Mammographically extremely 
dense (>50%) breasts compared to 
less dense (11-25%) 
!! One first-degree relative with BC 
1.1-2.0 !! Alcohol consumption 
!! Ashkenazi Jewish heritage 
!! Diethylstilbestrol exposure 
!! Early menarche (<12 years) 
!! Height (>5 feet 3 inches) 
!! High socioeconomic status 
 7 
!! Late age at first full-term 
pregnancy (>30 years) 
!! Late menopause (>55 years) 
!! Mammographically dense (26-
50%) breasts compared to less 
dense (11-25%) 
!! Non-atypical ductal hyperplasia or 
fibroadenoma 
!! Never breastfeeding 
!! No full-term pregnancies 
!! Obesity (postmenopausal)/adult 
weight gain 
!! Personal history of BC (40+ years) 
!! Personal history of endometrium, 
ovary, or colon cancer 
!! Recent or long-term use of 
menopausal hormone therapy with 
estrogen or progestin 
!! Recent oral contraceptive use 
This table shows the factors that increase the risk of breast cancer and their relative 
risk levels (American Cancer Society, 2015). 
 
 In April of 2015, a team of international researchers combined 77 of the common 
genetic variants into a single risk factor that can be used to improve the identification of 
women with a high risk of breast cancer (Mavaddat et al., 2015). The factor, known as 
the polygenic risk score, was built using the genetic date from more than 67,000 women 
(Mavaddat et al., 2015). The polygenic risk score can be used to place women into 
various risk categories. A woman in the top 1% was three times more likely to develop 
breast cancer when compared to a woman with an average polygenic risk score, and 
women in the bottom 1% had a 70% lower risk (Mavaddat et al., 2015). Results indicated 
that the polygenic score is as powerful as other well known risk factors, including 
familial history and breast density (Mavaddat et al., 2015). A sister study found that 
breast density and the polygenic risk score both contribute independently to breast cancer 
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risk (Vachon et al., 2015). When the polygenic risk score was combined with the risk 
stratification tool used by the Breast Cancer Surveillance Consortium (BCSC), which 
includes history of breast cancer, history of breast biopsy, age, and ethnicity to calculate 
risk, the performance of the model was improved – putting 11% of women who 
eventually developed cancer into a higher risk category (Vachon et al., 2015). The team 
is currently developing a test based on the results with hopes of using it to improve 
personalized breast cancer screening and prevention. However, future, larger studies are 
still critical to determine the ability of models to assess risk in the general population. 
While risk prediction and screening can be used to help improve early detection, it is still 
crucial to work to improve BC treatment-related issues in order to improve quality of life 
for those that survive the disease.  
 
Breast Cancer Treatment Overview  
The following section reviews the four most common treatment options for breast cancer 
in order to better understand later how treatment can impact sexual dysfunction, sexual 
identity, self-esteem, and intimate partner relationships.  
  
1.! Radiation Therapy  
2.! Endocrine Therapy  
3.! Chemotherapy  
4.! Breast Surgery  
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Radiation Therapy  
Radiation therapy is often needed if the cancer has spread to the lymph nodes or 
elsewhere in the body. There are two main types of radiation therapy used to treat BC: 
external beam radiation, radiation from a machine outside the body, and internal radiation 
or brachytherapy, radiation from a radioactive source inside the body (American Cancer 
Society, 2016b). Radiation is often used after breast-conserving surgery to help lower the 
risk of the cancer returning, after mastectomy, and if the cancer has spread (American 
Cancer Society, 2016b). External radiation, the most common type of radiation, is not 
typically started until the tissues have healed, and if paired with chemotherapy, it is 
usually delayed until after chemo is complete (American Cancer Society, 2016b). 
Traditionally, breast radiation was given five days a week for 5 to 6 weeks (American 
Cancer Society, 2016b). Doctors are now using accelerated breast irradiation, giving 
larger doses over a shorter time (American Cancer Society, 2016b). Side effects of 
external radiation include swelling and heaviness in the breast, skin changes (ranging 
from mild redness to blistering and peeling), and fatigue (American Cancer Society, 
2016b). Most skin changes subside in a few months, while changes to breast tissue 
subside in six to twelve months or longer (American Cancer Society, 2016b). Side effects 
of external radiation appearing later on include: smaller, firmer breasts, issues with 
breastfeeding, brachial plexopathy, lymphedema, weakness and fracture of the ribs, 
radiation-related scarring of the heart and lungs (rare), and development of angiosarcoma 
(very rare) (American Cancer Society, 2016b). Brachytherapy can be used in conjunction 
with external radiation for women who have had breast-conserving surgery to add extra 
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radiation to the tumor site. There are various types of brachytherapy: interstitial and 
intracavitary (American Cancer Society, 2016b). Interstitial brachytherapy involves 
catheters placed into the area where the cancer has been removed (American Cancer 
Society, 2016b). Radioactive pellets are placed into the catheters for short periods of time 
each day and removed; this method is older with more evidentiary support but is not used 
often (American Cancer Society, 2016b). During intracavitary brachytherapy, a device is 
put into the space operated on during breast-conserving surgery and is left until the 
treatment is complete (American Cancer Society, 2016b). It is placed in a catheter with 
one end protruding out from the breast (American Cancer Society, 2016b). Radiation 
sources (mostly pellets) are placed through the tube and into the device and then removed 
(American Cancer Society, 2016b). Treatments are done twice a day for five days, after 
which the device is removed (American Cancer Society, 2016b). Side effects of 
intracavitary brachytherapy include redness, bruising, breast pain, infection, break-down 
of fatty tissue in the breast, weakness and fracture of the ribs (rare) (American Cancer 
Society, 2016b).  
 
Endocrine Therapy  
Estrogen receptor positive (ER-positive) and progesterone receptor positive (PR-
positive) breast cancer cells grow in response to estrogen and progesterone, respectively.  
For these types of cancer, endocrine therapy is recommended. Most endocrine therapy 
drugs work by lowering estrogen levels or inhibiting estrogen receptors on cancer cells, 
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therefore inhibiting cell growth. It is most often used as adjuvant therapy but can be used 
as neoadjuvant therapy as well (American Cancer Society, 2016a).  
Tamoxifen, a selective estrogen receptor modulater (SERM), blocks estrogen 
receptors in breast cancer cells. It can be used in women with a high risk of breast cancer 
to help lower the risk (American Cancer Society, 2016a). Toremifene (Fareston) is 
another SERM that is used less often and is approved only to treat invasive, metastatic 
BC (American Cancer Society, 2016a). Side effects of tamoxifen and toremifene include 
fatigue, hot flashes, vaginal dryness or discharge, and mood swings (American Cancer 
Society, 2016a). Some women with cancer that has spread to bones may have “tumor 
flare”, pain or swelling in the muscles and bones (American Cancer Society, 2016a). In 
premenopausal women, tamoxifen can lead to bone thinning, but in postmenopausal 
patients, it augments bone strength (American Cancer Society, 2016a). Some more 
serious, rare complications include developing endometrial cancer and uterine sarcoma in 
postmenopausal women, blood clots (DVTs and PEs), strokes in postmenopausal women, 
and increased risk of myocardial infarction (American Cancer Society, 2016a). 
Fulvestrant (Flasodex) is a systemic estrogen antagonist. It is used most often to treat 
invasive breast cancer after tamoxifen and Aromatase inhibitors have stopped being 
effective (American Cancer Society, 2016a). Side effects (short term) include hot flashes, 
night sweats, mild nausea, fatigue, weaken bones. It is currently approved only for 
postmenopausal women (American Cancer Society, 2016a).  
Aromatase inhibitors (AIs) stop estrogen production and are most successful for 
women after menopause (American Cancer Society, 2016a). Letrozole (Femara), 
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Anastrozole (Arimidex), and Exemestane (Aromasin) are being used to treat BC 
(American Cancer Society, 2016a). This drug class has fewer severe complications than 
tamoxifen (American Cancer Society, 2016a). They can cause muscle pain, joint pain, 
and stiffness, and they can also cause bone thinning in women postmenopause, due to 
draining the body of estrogen, leading to osteoporosis and fractures (American Cancer 
Society, 2016a). The current recommendation for premenopausal women with high risk 
breast cancer is ovarian ablation or suppression and treatment with AIs (Zhang et al., 
2016). 
 
Chemotherapy  
Chemotherapy treats the whole body, not just the breast. It can be administered by mouth 
or intravenously. There are several side effects of chemotherapy, although women suffer 
different side effects from different combinations of agents (see Table 2). Not all women 
with BC need to go through chemotherapy, but it is recommended in some situations: 
adjuvant (after surgery), neoadjuvant (before surgery), and for advanced breast cancer 
(American Cancer Society, 2016d). The most common chemotherapy drugs include: 
Anthracyclines, such as doxorubicin (Adriamycin®) and epirubicin (Ellence®), Taxanes, 
such as paclitaxel (Taxol®) and docetaxel (Taxotere®), 5-fluorouracil (5-FU), 
Cyclophosphamide (Cytoxan®), and Carboplatin (Paraplatin®) (American Cancer 
Society, 2016d). They are often most successful when a combination is used (usually 2 or 
3) (American Cancer Society, 2016d). Advanced breast cancer chemotherapy drugs 
include: Docetaxel, Paclitaxel, platinum agents (cisplatin, carboplatin), Vinorelbine 
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(Navelbine®), Capecitabine (Xeloda®), Liposomal doxorubicin (Doxil®), Gemcitabine 
(Gemzar®), Mitoxantrone (Novantrone®), Ixabepilone (Ixempra®), Albumin-bound 
paclitaxel (nab-paclitaxel or Abraxane®), and Eribulin (Halaven®) (American Cancer 
Society, 2016d). Advanced breast cancer may be treated with a single drug, but  
combinations (carboplatin or cisplatin plus gemcitabine) are commonly used (American 
Cancer Society, 2016d). Chemotherapy drugs are given in cycles, which are commonly 2 
or 3 weeks long. Adjuvant and neoadjuvant chemo is given for 3 to 6 months total, 
depending on the drugs used (American Cancer Society, 2016d).  
 
Table 2. The short term and long term side effects of chemotherapy drugs  
Short Term 
 (subside when chemo finishes) 
Long Term 
Hair loss, Nail Changes Neuropathy 
Mouth sores Hand-food syndrome 
Loss of appetite or increased appetite Fatigue 
Nausea and vomiting Heart damage 
Increased chance of infections Premature menopause, infertility  
Easy bruising or bleeding Increased risk of leukemia (rare) 
Fatigue  
Diarrhea  
There are various short term and long term effects due to chemotherapy drugs that 
affect many separate body systems (American Cancer Society, 2016d). 
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Breast Surgery  
The type of breast surgery performed depends on: the size of the cancer in the breast, 
whether it has spread, the size of the breasts, personal feelings, thoughts, wishes 
(American Cancer Society, 2016c). There are a multitude of breast surgeries – simple or 
total mastectomy, modified radical mastectomy, radical mastectomy, skin-sparing 
mastectomy, nipple-sparing mastectomy, lumpectomy or wide local excision surgery, 
lymph node surgery, and breast reconstruction (or BR, of which there are multiple types) 
(American Cancer Society, 2016c). During the simple or total mastectomy, the surgeon 
removes the entire breast including the nipple; the lymph nodes are not removed 
(American Cancer Society, 2016c). This is the most appropriate option if the cancer is not 
present in the lymph nodes and if the surgery is done to lower risk of getting breast 
cancer (American Cancer Society, 2016c). With a modified radical mastectomy, all of the 
breast tissue, nipple, and lymph nodes in axilla are taken, which is preferred if the cancer 
is invasive to the lymph nodes (American Cancer Society, 2016c). During the radical 
mastectomy, the surgeon removes all of the breast tissue and nipple, the lymph nodes of 
the armpit, and the muscles of the chest wall under the breast (American Cancer Society, 
2016c). This is rarely done at present since the modified radical mastectomy is effective 
and less disfiguring, but is conducted if the cancer has spread to the chest muscles 
(American Cancer Society, 2016c).!With the skin sparing mastectomy, the skin of the 
nipple, areola, and the area with the tumor are all taken out, leaving behind the rest of the 
skin to be used for breast reconstruction (American Cancer Society, 2016c). Nipple-
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sparing mastectomies are similar to skin-sparing surgeries, but the areola is left intact and 
only the glandular tissue is removed. During a lumpectomy (also known as a partial 
mastectomy or wide local excision), the surgeon removes the tumor and some 
surrounding breast tissue. Radiation treatments are likely needed as well with this option 
(American Cancer Society, 2016c). There are a two types of common lymph node 
surgeries. The axillary lymph node dissection (ALND), during which 10 to 20 lymph 
nodes from under the arms are removed, and the sentinel lymph node biopsy, where the 
surgeon finds and removes the lymph nodes where the cancer would most likely have 
spread to first (American Cancer Society, 2016c). Breast reconstruction (BR) with 
implants or tissue from the lower abdomen, buttocks, back, or inner thighs can be used to 
reconstruct the breast after a mastectomy (American Cancer Society, 2016c).  
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SPECIFIC AIMS  
 
Myths and issues in our society result in barriers to conversations about sexuality 
in women with breast cancer. One myth in particular is the notion that women with breast 
cancer and survivors are no longer concerned with sexuality and intimacy. Sexuality and 
sexual function in a woman with or post breast cancer need to be considered regardless of 
the woman's age, partner status, and disease stage. One aim of this paper is to present 
research related to changes in a woman's sexuality, self-concept, and intimacy after the 
management of breast cancer to provide strategies for clinicians to use in communicating 
openly about sexuality, as well as to provide loved ones, and intimate partners with 
support strategies and tools for a similar open communication. Another aim is to present 
findings related to changes in intimate partner relationships with a focus on the 
experience of the intimate partner as the primary support system in order to give medical 
professionals an insight into the struggles of the couple as a unit. The intimate partner 
provides a unique support system, and the hope is that this paper shows the protective 
value of a strong relationship and supportive partner against the sexual issues that can 
arise in association with breast cancer treatment. The aim of this paper is finally to give a 
research direction for possible treatments for sexual dysfunction, intimacy, and sexuality 
concerns in breast cancer survivors in order to improve quality of life for these women.
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IMPACT OF TREATMENT:  
PHYSCIAL CHANGES – SEXUAL DYSFUNCTION 
 
While handling guilt, anxiety about the future, and the fear of potential treatment 
side effects, it is not surprising that sexual problems arise due to breast cancer. Although 
most cancer causes problems in some area of sexual life, breast cancer is uniquely 
important to consider due to breasts’ role in feminine sexuality and role as a source of 
erotic pleasure and stimulation. Breast cancer treatments all have direct and indirect 
effects related to sexual function (Sadovsky et al., 2010).  
Findings show that when compared with healthy, age-matched women, women 
with breast cancer have less sexual satisfaction and more difficulty maintaining their 
sexual life (Speer et al., 2005). Each form of treatment may affect sexual function in a 
different way, but it is of concern that regardless of the type of treatment received, 
women treated for BC experience sexual dysfunction. This section will present published 
research on the various areas of sexual dysfunction for each of the major breast cancer 
treatment options.  
 
Radiation Therapy  
Radiation therapy (RT) is a crucial component of therapy for BC patients treated 
with breast conserving therapy/surgery (BCT) and patients with high risk cancers that 
necessitate mastectomy (ME), including those women where chemotherapy was chosen 
in place of surgery (Boswell & Dizon, 2015). RT can result in local breast issues, such as 
constant breast pain, arm and shoulder pain, loss of flexibility, and lymphedema, which 
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contributed to depressed sexual functioning (Albornoz et al., 2014; Hidding, Beurskens, 
van der Wees, van Laarhoven, & Nijhuis-van der Sanden, 2014; Safarinejad, Shafiei, & 
Safarinejad, 2013). Safarinejad et al. found that treatment with RT had significantly 
increased risk of lubrication and satisfaction disorders (Safarinejad et al., 2013).  
Albornoz et al., found that in women who underwent breast reconstruction (BR), 
those who had also undergone RT were significantly less satisfied with the breasts and 
the outcome (Albornoz et al., 2014). The women treated with RT had significantly lower 
scores for sexual well-being (Albornoz et al., 2014). Despite all of the evidence, it is hard 
to pinpoint the exact reason for radiation therapy’s negative impact on and contribution to 
sexual dysfunction and sexual health because it is almost always used in conjunction with 
other BC treatments in an interdisciplinary manner.  
  
Chemotherapy  
Many women with BC undergo chemotherapy (often adjuvant chemotherapy). 
For women who are not yet menopausal, chemotherapy has a risk of chemotherapy-
induced ovarian failure and the onset of early menopause, which can cause sexual 
dysfunction issues (Boswell & Dizon, 2015). Agents such as anthracyclines and taxanes 
negatively affect general physical functions, reducing interest, arousal, and desire 
(Boswell & Dizon, 2015). In addition, common side effects of chemotherapy, including 
fatigue, alopecia, gastrointestinal distress, and myelosuppression, can affect desire and 
arousal (Boswell & Dizon, 2015). A study in 2010 found that sexual functioning, desire, 
and arousal all declined significantly following chemotherapy (Biglia et al., 2010). Some 
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women can experience a relief of changes in sexual functioning after chemotherapy 
finishes, but Biglia et al. found that these changes persisted at one year following 
chemotherapy (Biglia et al., 2010). Another study found that chemotherapy was 
associated with unmet sexual needs, which were reported less than a year from the end of 
treatment and also more than three years after treatment (Hwang, Chang, & Park, 2013).  
 
Endocrine Therapy 
Anti-estrogen therapies (including tamoxifen) have large negative effects on 
sexual and vaginal health (Derzko, Elliott, & Lam, 2007). Anti-estrogen therapies lead to 
increased endometrial abnormalities, such as more polyps, more hyperplasia, and a higher 
risk of endometrial cancer (Derzko et al., 2007). They lead to more hot flashes, vaginal 
bleeding and discharge and cause issues besides genital functioning that affect sexual 
health, including bladder and bowel difficulties, mobility limitations, and fatigue (Derzko 
et al., 2007). Consequently, aromatase inhibitors (AIs) have become the premier adjuvant 
therapy option for postmenopausal women with hormone receptor positive (HR+) breast 
cancer to prevent recurrence and second primary tumors (Burstein et al., 2014). 
Beginning endocrine therapy with an AI or switching to an AI after taking tamoxifen has 
been shown to be significantly better than tamoxifen alone in preventing breast cancer 
from recurring (Burstein et al., 2014). It is still unclear whether AIs provide a more 
robust chance of survival than tamoxifen treatment (Burstein et al., 2014). The American 
Society of Clinical Oncology updated the clinical practice guideline for adjuvant 
endocrine therapy with HR+ breast cancer in 2014 (Burstein et al., 2014). According to 
 20 
that guideline, there are options of an aromatase inhibitor (AI) for 5 years or tamoxifen 
for 5 years followed by 5 more years of an AI (Burstein et al., 2014). Goss et al. (2011) 
and Cuzik et al. (2014) both showed promising results for AIs used for primary 
prevention in postmenopausal women at high risk for breast cancer. After such studies, 
AIs are more often prescribed than tamoxifen for the postmenopausal population 
(Burstein et al., 2014). Premenopausal women were not able to have AIs because they 
require non-functional ovaries (Pagani et al., 2014). However, the option of ovarian 
suppression along with an AI is now an alternative to tamoxifen (with or without ovarian 
suppression) (Pagani et al., 2014). The current clinical recommendation is to put young 
women at higher risk on AIs with ovarian suppression, which has profound negative 
impacts on sexual and vaginal health, including increased hot flushes and vaginal dryness 
(Zhang et al., 2016). The idea here is that for the higher risk young patients, the benefits 
outweigh the harms. Three AIs frequently used, exemestane, letrozole, anastrozole, seem 
to have comparable sexual side effects overall (Hadji et al., 2013; Ziller et al., 2009). 
Table 3 shows the various sexual dysfunctions and their prevalence in women treated 
with AIs (Schover, Baum, Fuson, Brewster, & Melhem-Bertrandt, 2014). 
 
Table 3. Sexual function in women on aromatase inhibitors (AIs) 
Publication N Months on AIs 
Low sexual 
desire % 
Vaginal 
dryness % Dyspareunia % 
Morales et!al. 2004 37 3 68 50 62 
Cella et!al. 2006 335 60 34 18 17 
Jones et!al. 2007 808 12 58 50 — 
Antoine et!al. 2008 14 Unknown 84 88 — 
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*Item was reported as “sexual problems” so it may reflect more than low desire. 
 
These are the various sexual issues and percentage of women affected will on AIs in 
publications since 2004 (Schover, Baum, Fuson, Brewster, & Melhem-Bertrandt, 
2014).  
 
At least a third of women in most studies reported low sexual desire, vaginal dryness, and 
dyspareunia. Schover and colleagues do point out limitations that are problematic for 
understanding these data. It is not clear whether sexually inactive women were excluded 
or included in the studies. Women not having sex may not be aware of sexual changes 
(Schover et al., 2014). 
Endocrine therapy agents are associated with the onset and/or worsening of 
menopausal symptoms, including hot flashes, which can negatively impact sexual 
function and health (Boswell & Dizon, 2015; Morales et al., 2004). 30-40% of women 
being treated with tamoxifen have sexual complaints, and over 50% of women on AIs 
report similar sexual problems (Boswell & Dizon, 2015). Women treated with AIs or 
tamoxifen have similar scores for quality of life, menopause symptoms, hot flashes, and 
fatigue (Baumgart, Nilsson, Evers, Kallak, & Poromaa, 2013; Cella et al., 2006; Frechette 
et al., 2013). AIs have been found much more likely to increase vaginal dryness, 
dyspareunia, and arthralgias than tamoxifen (Castel et al., 2013; Frechette et al., 2013; 
Morales et al., 2004). In one study by Morales et al., AIs were found to increase 
Oberguggenberger et!al. 
2011 233 Unknown 51 32 16 
Baumgart et!al. 2013 35 Unknown — 42 62 
Kyvernitakis et!al. 2014 181 24 43* 57 — 
Aiello Bowles et!al. 2012 314 Unknown 36 36 — 
Fallowfield et!al. 2012 83 24 32 17 13 
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dyspareunia while tamoxifen decreased sexual interest (Morales et al., 2004). The two 
agents impact sexual health in differing areas, but both negatively impact sexual health. 
A more recent study compared postmenopausal women with BC taking either tamoxifen 
(with or without estrogen) or an AI (with or without estrogen) with age matched women 
with no history of cancer of two groups, currently taking estrogen and not currently 
taking estrogen (Baumgart et al., 2013). Sexual activity was similar across all groups 
(Baumgart et al., 2013). Women on AIs were unsatisfied with their sex life overall 
(42.4%) and reported significantly less sexual interest (50%) than the tamoxifen-treated 
group and the two control groups (Baumgart et al., 2013). AI-treated patients had more 
issues with lubrication (73.9%) and dyspareunia (56.5%) than controls (both taking and 
not taking estrogen) (Baumgart et al., 2013). Interestingly, tamoxifen-treated patients had 
more dyspareunia (31.3%) but scored about the same as the control groups in all of the 
other areas (Baumgart et al., 2013). Orgasmic dysfunction was not statistically different 
for those taking AIs or tamoxifen (50% and 42%, respectively) (Baumgart et al., 2013). 
This study’s results suggest that AIs have a greater negative effect on sexual function 
than tamoxifen (see Table 4). However, this study only used postmenopausal women 
with or without BC. Morales et al. (2004) found tamoxifen and AIs impacted desire and 
dyspareunia (respectively), independently of age. This study did, however, show that 
younger women had increased hot flashes and vaginal dryness with both agents, 
suggesting there can be age differences in at least those two areas of sexual functioning 
(Morales et al., 2004).  
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Table 4. Various effects of AIs and Tamoxifen on sexual dysfunction  
Sexual Dysfunction Type % of AI-treated Group 
Affected  
% of Tamoxifen-treated 
Group Affected 
Insufficient lubrication 74%* 40%* 
Dyspareunia 57%* 31% 
Orgasmic Dysfunction 50% 42% 
*=significant difference from controls 
 
These results from Morales et al. (2004) demonstrate AIs having a greater negative 
impact in all three areas of sexual dysfunction than tamoxifen.  
 
A study by Schover et al., found that during the first two years of AI therapy, 93% 
met the specific criteria for sexual dysfunction on the FSFI (Female Sexual Function 
Index), and 75% reported distress as a consequence of sexual issues (Schover et al., 
2014). Almost 25% of women studied who were sexually active at the start of endocrine 
therapy stopped having sex as a result of these sexual issues (Schover et al., 2014). These 
women were not investigated throughout and after endocrine therapy so it is unclear 
whether or not sexual dysfunction remains prominent after therapy has concluded. 
Further research is needed to find the long-term effect of endocrine therapy on sexual 
function, which should include studies with premenopausal women. However, research 
suggests that the majority of women being treated with AIs, the most popular option for 
endocrine therapy, are experiencing sexual dysfunction in one area or another that is 
distressing and difficult to overcome.  
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Breast Surgery  
Breast surgery can result in physical changes in sexual function. There is evidence 
that conserving breast therapy or surgery (BCT) has less of a negative impact on sexual 
function than simple mastectomies (ME) (Boswell & Dizon, 2015). A prospective study 
of women with early-stage breast cancer found that post-operative sexual function scores 
were significantly lower than pre-operative scores in both the mastectomy (ME) and 
breast conserving therapy or surgery (BCT) group (Aerts, Christiaens, Enzlin, Neven, & 
Amant, 2014). Compared to their pre-operative scores, significantly more women in the 
BCT group reported problems with sexual arousal after six months following surgery, 
while significantly more women in the ME group had problems with sexual desire, 
arousal, ability to achieve orgasm both six months and one year after breast surgery 
(Aerts et al., 2014). In the ME group women also reported problems with intensity of 
orgasm (Aerts et al., 2014). Another study found similar results after evaluating close to 
1,000 women over five years following breast surgery (Engel, Kerr, Schlesinger-Raab, 
Sauer, & Hölzel, 2004). Women who underwent ME had more disruption in their sex 
lives than those who underwent BCT (Engel et al., 2004). Even more important, while 
some issues improved over time, issues with sexual functioning did not, plaguing these 
women for at least five years (Engel et al., 2004).  
When it comes to reconstructive surgery, there is conflicting evidence on the 
impact on sexual dysfunction. Some studies do suggest an improved sexual health 
associated with breast reconstructive surgery (Atisha et al., 2008; Ganz, 1997). However, 
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contradicting evidence exists as well. A study by Metcalfe et al. found that women who 
had ME alone, and ME with either immediate or delayed reconstruction had no 
significant differences in sexual function one-year post-op (Metcalfe et al., 2012). It is 
clear that all treatment options for breast cancer cause various types of sexual dysfunction 
of various degrees of severity. The staggering numbers of women suffering from these 
distressing issues show the impact that BC treatment can have. It is therefore important to 
include these risks as part of the conversation surrounding breast cancer treatment and 
life as a survivor. BC treatment can also understandably affect psychosocial areas 
including self-esteem and body image. The next section will present research published 
on these psychosocial changes associated with management of breast cancer.  
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IMPACT OF TREATMENT: PSYCHOLOGICAL CHANGES – 
 
ALTERED SELF-ESTEEM, BODY IMAGE, AND SEXUAL SELF-CONCEPT 
 
With a diagnosis of breast cancer come various psychosocial issues, and often the 
greatest of challenges relate to sexual function, body image, and sexual self-concept. 
Body image is the mental picture of one’s body and is a component of a large concept of 
self that for many women involves feeling feminine and attractive, although each woman 
experiences her body differently (Cohen, Kahn, & Steeves, 1998). Research has found 
that older women experience more body image issues with breast cancer than with 
gynecological cancers (Gómez-Campelo, Bragado-Álvarez, & Hernández-Lloreda, 
2014). A key study done by Pikler and Winterowd found that the more positive a 
woman’s body image, the better she coped with cancer, and with the better body image 
came higher levels of self-confidence towards coping with breast cancer (Pikler & 
Winterowd, 2003). In addition, body image has been found to be correlated with sexual 
problems (Fobair et al., 2006). It is important to consider the psychosocial effects of 
breast cancer treatment in order to find interventions for improving self-esteem, body 
image, and sexual self-concept and perhaps to help remedy sexual problems caused by 
treatment. While the majority of this type of research focuses on breast cancer surgery, 
this section presents how each of the common treatments for breast cancer can impact 
self-esteem, body image, and sexual self-concept.   
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Radiation and Endocrine Therapy 
The majority of research on the effects of RT on body image, self-esteem, and 
sexual self-concept uses participants who have undergone breast surgery (or another 
treatment option) as well as RT, since this is a common treatment combination. 
Therefore, it is difficult to find the specific impact that RT has. Albornoz et al. found that 
women treated with RT after BR had significantly lower scores of psychosocial well-
being than women who only had BR (Albornoz et al., 2014). A study by Chang and 
colleagues found that for women treated with both breast cancer surgery and RT, 
significantly poorer body image and higher distress was associated with unemployment, 
when the model was fully adjusted (Chang et al., 2014). In addition, after correcting the 
model for age, disease stage, present treatment status, and type of breast surgery, higher 
body image was positively correlated with higher education and family income (Chang et 
al., 2014). These results, demonstrating that socioeconomic status had an impact on body 
image and quality of life for these women, further complicates how RT impacts body 
image (Chang et al., 2014).  
Much of the research conducted on women who are undergoing or who have been 
treated with endocrine therapy for breast cancer in the past focuses on the physical side 
effects of the treatment, and few studies addressed the psychological impact of endocrine 
therapy (Rosenberg, Stanton, Petrie, & Partridge, 2015). Kraus’s data shows that 
distorted body image due to breast cancer treatment is more pronounced if hormonal or 
chemotherapy is added to the treatment schedule (Kraus, 1999). In this case, however, it 
is hard to analyze the exact effects of hormone therapy on body image. Aerts and 
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colleagues found that for women being treated with tamoxifen or AIs, emotional distress 
was correlated negatively with self-esteem (Ates et al., 2016). For those women, higher 
self-esteem meant a lower level of emotional distress (Ates et al., 2016). This finding 
suggests that self-esteem can have a protective effect from emotional distress due to 
endocrine therapy.  
 Breast cancer survivors often receive adjuvant endocrine therapy (AET) long-
term to reduce the risk of the cancer recurring (Van Londen et al., 2014). In one study on 
this particular group of women, over 50% of participants were currently experiencing 
identity and sexual difficulties (Van Londen et al., 2014). A higher number of concerns 
was associated with the receipt of chemotherapy, suggesting that chemotherapy played an 
important role in psychological disturbances for these women (Van Londen et al., 2014).  
 
Chemotherapy 
Cytotoxic chemotherapy causes hair loss and weight gain or loss, which can affect 
a women’s sexual self-concept and, in turn, their sexual experience (Pinto, 2013). Biglia 
and colleagues (2010) found that sexual function, desire, and arousal all worsen at one 
year following chemotherapy for breast cancer. These changes were not associated with a 
worsening sense of body image (Biglia et al., 2010). However, some studies point to 
chemotherapy causing a worsening in body image and self-esteem (Fobair et al., 2006; 
Hwang et al., 2013). Fobair and colleagues found that greater body image issues were 
associated with hair loss due to chemotherapy (Fobair et al., 2006).  
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In a larger, recent study of 534 women, Hwang and colleagues found that women 
who had undergone chemotherapy for breast cancer had a significantly worse quality of 
life than women who did not have chemotherapy (Hwang et al., 2013). Chemotherapy 
was associated with depression, unmet sexual needs, and a lower emotional well-being 
(Hwang et al., 2013). These findings were predominantly reported acutely (less than 1 
year from end of treatment) but also appeared to be present later (more than 3 years out 
from treatment), suggesting a long-term component to the psychosocial effects of 
chemotherapy (Hwang et al., 2013). However, more research is needed on the long-term 
effects on breast cancer survivors and their self-esteem, self-concept, and body image.  
 
Breast Surgery  
 BC management has recently been shifting to include considerations for improved 
quality of life. Although BR and implants may mask breast loss to the outside world, 
implants are not incorporated into the woman’s body image and does not always help 
cure her sense of deformity (Al-Ghazal, Fallowfield, & Blamey, 2000). Breast conserving 
surgeries (such as the wide local excision procedure) are therefore now the premier 
choice for most patients (“Types of breast cancer surgery | Cancer Research UK,” n.d.). 
However, this method is not always an available option for some patients, such as those 
with multiple tumors or widespread ductal in situ carcinoma.  
 In these cases, mastectomy is preferred since it promises the highest local control 
of the cancer. However, mastectomies also result in significant changes to body image 
that cause emotional and psychological stress for many patients (Curran et al., 1998). 
 30 
Women treated with mastectomy reported life disruptions and significantly lower scores 
in body image, role, and sexual life (Engel et al., 2004). In any surgery, the cosmetic 
outcome is important for patient satisfaction.  
 Breast-conserving surgery is associated with an improved quality of life compared 
to a simple mastectomy. There have been published studies that have found no difference 
in quality of life between the two treatment modalities after a long-term follow up, but 
they have found superior body image in patients undergoing breast-conserving surgery 
(Jeffe, Pérez, Cole, Liu, & Schootman, 2016). Jeffe and colleagues explained this finding 
due to the fact that quality of life is affected not only by the type of surgery performed 
but also by the cancer diagnosis and fear of recurrence (Jeffe et al., 2016).  
When it comes to reconstructive surgery, there is conflicting evidence on the 
impact on psychosocial well-being. Atisha et al., evaluated responses from 116 women 
who had immediate reconstruction and 57 women with delayed reconstruction. Body 
image and psychological well-being improved from pre-operative scores (Atisha et al., 
2008). The women were thriving regardless of the type of procedure performed. The 
general psychosocial benefits and improved body image scores continued to be observed 
2 years following surgery (Atisha et al., 2008). Metcalfe et al., found that women who 
had ME alone, ME with immediate, and ME with delayed reconstruction had no 
significant differences in quality of life, cancer-related distress, body image, anxiety or 
depression after one year following surgery (Metcalfe et al., 2012). This suggests women 
need psychosocial support even with reconstruction (Metcalfe et al., 2012). 
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Much of the research shows changes in body image and self-esteem post breast 
surgery. In a study by Fobair and colleagues, half of the partnered women experienced 
two or more body image problems sometimes or at least one problem most of the time 
following breast surgery (Fobair et al., 2006). The group found that serious problems 
were rather infrequent, such as feeling self-conscious or embarrassed by their body a lot 
of the time (reported by 10%), feeling worried about sexual attractiveness (10%), and 
feeling less feminine (7%) (Fobair et al., 2006).  Similar to previous studies, the group 
found that greater body image problems were reported with mastectomies (Fobair et al., 
2006). In a very recent study, Rojas and colleagues studied women who underwent 
radical mastectomies, skin-sparing (SSM), and nipple-sparing (NSM) mastectomies 
(Rojas et al., 2017). The NSM group had the least satisfaction with post-operative 
appearance and lowest median sexual desire (Rojas et al., 2017). While NSM offers the 
greatest opportunity to preserve the patient’s own skin, the results of this study do not 
support better body image or greater surgical aesthetic outcome (Rojas et al., 2017). The 
group suggests that surgeons should be realistic with patients in terms of aesthetic and 
functional outcomes so that patients can make an informed decision prior to surgery 
(Rojas et al., 2017). 
 Markopolous et al. conducted a retrospective study with patients with stage 1 or 2 
BC treated with either wide local excision (WLE) and axillary lymph node clearance 
(breast-conserving or WLE group), modified radical mastectomy without reconstruction 
(MRM group), or by mastectomy with delayed breast reconstruction (BR group) 
(Markopoulos et al., 2009). The groups were given two questionnaires, part 1 and 2. Part 
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1, about body image, was given 12 months after surgery and consisted of yes/no 
questions, while Part 2 was specific to each type of surgery (Markopoulos et al., 2009). 
The researchers found that the WLE group had the most satisfaction with treatment 
overall but reported reduction in sexual willingness, and the BR group reported the least 
problems in sexual life (Markopoulos et al., 2009). 94% of the WLE group stated they 
would choose that surgery again (Markopoulos et al., 2009). The majority of the WLE 
group and many in the BR group were satisfied with their outcomes; over 75% of the 
WLE group were very satisfied with body image, total cosmetic outcome, and surgical 
outcome (Markopoulos et al., 2009). The MRM group was the least satisfied with their 
surgery, body image, and sex life (Markopoulos et al., 2009). The results were consistent 
with a previous study that found immediate reconstruction produced less distress and a 
better psychological status compared with delayed reconstruction (Curran et al., 1998). 
Overall the results showed that breast-conserving (wide local excision) surgery had the 
least detrimental impact on self-esteem, body image, and sexual life and that delayed 
reconstruction is better than no reconstruction at all (Markopoulos et al., 2009).  
 Nano et al. found a significant difference between mean body image score of a 
mastectomy group (40.73) and the mean scores of the breast-conserving group (44.39), 
and the BR group (41.99). The ages at diagnosis were oldest in the mastectomy group 
and youngest in the BR group (Nano et al., 2005). These results suggest that sexuality 
and body image may be slightly more important for women diagnosed with breast cancer 
earlier in life (Nano et al., 2005). However, the BR group still had the highest levels of 
satisfaction (Nano et al., 2005). This group of patients typically has extensive interviews 
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and counseling before their surgery, possibly influencing satisfaction levels, according to 
the researchers (Nano et al., 2005). The study also evaluated the surgeries based on the 
breasts look and feel compared to the original breasts. The BR group reported their 
breasts looked more similar to the original breasts than the conserving group, and the 
conserving group reported their breasts feeling more similar to the original breasts than 
the BR group however (Nano et al., 2005). This may reinforce the finding that 30% of 
breast conserving surgeries result in significant breast deformities (Dewar et al., 1988; 
Johansen et al., 2002). The difference in quality of life between the three procedures is 
hard to say, but this study demonstrated the importance of breast conserving surgeries 
and BR in maintaining and perhaps improving body image. The highest satisfaction and 
best cosmetic outcome scores for the BR group demonstrate the superior results that can 
be achieved with breast reconstruction over conservation surgery.  
 Al-Ghazal and colleagues (2010) conducted a study to compare psychological 
aspects and patient satisfaction following WLE, simple mastectomy, and immediate BR. 
When it came to satisfaction, 91% of the WLE group was very much or moderately 
satisfied with the cosmetic outcome compared with 80% of the BR group and 73% of the 
simple mastectomy group (Al-Ghazal et al., 2000). Body image was reported 
significantly higher by women in the WLE group and lowest in the mastectomy group 
(Al-Ghazal et al., 2000). Similarly, self-esteem was better in the WLE group and worst in 
the simple mastectomy group (Al-Ghazal et al., 2000). The wide local excision group had 
less changes to body image and less extensive disfiguring than the breast reconstruction 
and simple mastectomy groups, which could have resulted in a higher patient satisfaction 
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with the cosmetic outcome (Al-Ghazal et al., 2000). Wide local excision is the obvious 
choice in operative procedures according to this study but is only available for a small 
group of breast cancer patients. Also of note, Ignacio Arrars and colleagues 
longitudinally studied premenopausal breast cancer survivors  and found that post-
mastectomy survivors had a four-fold greater risk of low body image scores, meaning 
these body image effects due to surgery can last long into survivorship (Ignacio Arraras 
et al., 2016). Therefore, BR should be offered for all patients that require mastectomy, as 
it allows for better body image and self-esteem levels and a subsequent higher quality of 
life. 
 The type of breast reconstruction has implications for body image and patient 
satisfaction. Sgarzani and colleagues studied body image and patient satisfaction for 
women who underwent breast reconstruction with either implants or autologous tissue 
reconstruction, where the tissue was a deep inferior epigastric perforator (DIEP) flap 
(Sgarzani et al., 2015). The DIEP group had a significantly higher level of satisfaction 
with the surgical outcome than the implant group (Sgarzani et al., 2015). The DIEP group 
also had higher levels on measures of quality of life, including psychosocial well-being, 
body image, sexual well-being, and physical well-being, but these results did not reach 
significance (Sgarzani et al., 2015). Yueh and colleagues evaluated patient satisfaction in 
patients who underwent tissue expander/implant, latissimus, pedicle transverse rectus 
abdominis muscle (TRAM), and deep inferior epigastric perforator (DIEP) flap 
reconstructions (Yueh et al., 2010). The DIEP group had the highest general level of 
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satisfaction (Yueh et al., 2010). Health-related quality of life was identified as a 
significant covariate influencing patient satisfaction (Yueh et al., 2010).  
These results suggest that autologous tissue reconstruction appears to have better 
psychological outcomes than implant reconstruction, with DIEP being the best 
autologous tissue option.   
Sexual self-concept can also be compromised with breast surgery. Wilmoth 
(2001) conducted a study with 18 women of an average 50.5 years of age to study the 
sexual side effects of breast cancer treatment. All of the women had undergone breast 
surgery; 7 women had lumpectomies and 11 women had mastectomies (Wilmoth, 2001). 
Wilmoth observed “losses” in four areas regardless of the type of surgery performed: 
“missing parts, loss of bleeding and becoming old, loss of sexual sensations, and loss of 
womanhood” (Wilmoth, 2001). Wilmoth coined the term “altered sexual self” to describe 
the adjustment to the sexual side effects of breast cancer surgery (Wilmoth, 2001). For 
these women, learning to adjust to the new sexual self was the main way to live beyond 
the cancer (Wilmoth, 2001). Our understanding of the ways breast surgery impacts body 
image, self-esteem, and sexual self-concept does have significant limitations, as most of 
the research on sexual self-concept fails to address how psychosocial issues change over 
time for survivors. Further research is needed to show how psychosocial changes 
continue later into survivorship.  
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IMPACT OF TREATMENT:  
INTIMATE RELATIONSHIP CHANGES   
 
Historically, research has explored the effects of breast cancer on sexuality and 
intimacy in regards to women experiencing satisfying sexual activity, their contentment 
with the frequency of sexual activity, and their physical sexual dysfunction (Wilmoth, 
2001). Functionally, sexuality was thought of as penile/vaginal intercourse (Wilmoth, 
2001). However, research has shown that sexual intercourse is not the main sexual 
concern after breast cancer and that sexual satisfaction is not always limited to sexual 
intercourse (Wilmoth, 2001). The primary focus on physical effects due to breast cancer 
treatment does not address the influence of the social and relational aspects of sexuality 
and illness, as well as how the meaning of sex varies to each individual and each intimate 
couple (Ussher et al., 2012). For breast cancer survivors in partnered relationships, the 
most important and consistent predictors of sexual health are presence/absence of vaginal 
dryness, emotional well-being, quality of the relationship, and if partner has sexual 
problems (Sadovsky et al., 2010). Of those factors, one of the strongest and most 
consistent predictors of sexual health after breast cancer is the quality of the partnered 
relationship (Ganz, Desmond, Belin, Meyerowitz, & Rowland, 1999). The quality of the 
relationship has been found to be a stronger predictor of sexual functioning, satisfaction, 
and desire after breast cancer than the physical damage to the body due to treatment 
(Alder et al., 2008). A healthy relationship status and supportive intimate partner have 
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been shown to help a woman cope with cancer (Archibald, Lemieux, Byers, Tamlyn, & 
Worth, 2006). 
Studies have also shown that cancer can have a positive effect on partner 
relationships by improving intimacy and in turn, bringing the couple closer together 
(Badr & Taylor, 2009). Unfortunately, however, most research consistently shows the 
negative impact of breast cancer on intimate partner relationships. Ussher et al., (2012) 
found that out of 1999 respondents, 24% said their sexual relationship was affected 
“dramatically”; 26%, “considerably”; 32%, “somewhat”; and only 15%, “not at all.”  
Many studies show evidence that the diagnosis of cancer can change the relational 
dynamics between the person with cancer and their life partner, which can in turn affect 
their sexual life (Gilbert, Ussher, & Hawkins, 2009). A review by Taylor-Brown and 
colleagues proposes the importance of clinicians’ query about the quality of martial and 
partner relationships, as it seems to be a main predictor of post-diagnosis marital 
adjustment (Taylor-Brown, Kilpatrick, Maunsell, & Dorval, 2000). This section will 
present research on breast cancer treatment’s negative effects in two extremely important 
areas of intimate partner relationships: sexual intimacy and emotional intimacy.  
 
Sexual Intimacy  
The research presented in previous sections of this paper show the numerous areas 
of sexual function and life that are affected by breast cancer treatment. Relationship 
changes in sexual intimacy are one way to analyze how detrimental these sexual effects 
of breast cancer treatment can be. One study showed a significant reduction in kissing, 
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caressing, and sexual intercourse after cancer (Ussher, Perz, & Gilbert, 2015). About half 
of participants in one study reported disappointment at the loss of sexual intimacy and 
feelings of inadequacy as consequences of changes in sexuality after cancer (Ussher et 
al., 2015). A separate study found that 78% of women report a decreased frequency of 
sexual activity after breast cancer treatment, and 48% report less satisfaction with sex 
(Ussher et al., 2012). Sixty percent of these women report a decreased satisfaction of 
intimacy, and 46.5% report a fear of rejection (Ussher et al., 2012). Gilbert and 
colleagues showed that reports of cessation or a reduction in sexual activities are 
associated with reductions in sexual satisfaction (Gilbert, Emilee, Ussher, & Perz, 2010) . 
Hawkins and colleagues found that 84% of partners caring for a person with 
“reproductive” cancer, including breast cancer, reported a negative impact on their sexual 
relationship (Hawkins et al., 2009). Cessation of sex or decreased frequency of sex was 
reported more than half the time by partners (Hawkins et al., 2009). A little less than 20% 
of partners reported renegotiating intimacy after breast cancer (Hawkins et al., 2009). 
Other changes in sexuality after cancer were associated with self-blame, lack of sexual 
fulfillment, and rejection (Hawkins et al., 2009). Sexual well-being is a central 
component to quality of life, and disrupting intimate relationships can cause significant 
distress (Mercadante, Vitrano, & Catania, 2010; “The World Health Organization Quality 
of Life assessment (WHOQOL),” 1995). In the absence of sexual activity, further 
relationship changes can include changes in emotional intimacy.  
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Emotional Intimacy  
Intimacy can be defined as emotional closeness, even in the absence of sexual 
activity. Perz et al. (2013) questioned patients, their partners, and their health care 
providers. The group confirmed that clinicians view sexual health most often as physical 
whereas patients and their partners emphasized emotional intimacy as important and 
highly valued, even in the absence of a physical sexual relationship (Perz, Ussher, & 
Gilbert, 2013). Hawkins and colleagues found that one positive consequence of 
relationship changes was accepting the changed sexual relationship and increasing 
closeness (Hawkins et al., 2009). A number of participants in a different study reported 
vastly different relationship changes as a result of sexual changes after cancer: 
relationship strain or termination and strengthened relationships (Ussher et al., 2015). It is 
uncertain what factors determine if a couple will grow closer or have increased tension in 
(or termination of) the relationship after breast cancer and its treatment. Perhaps couples 
can experience tension followed by a strengthened relationship. Ussher and colleagues 
hypothesize that the responses of partners took into account a positive bolstering of the 
relationship (Ussher et al., 2015). These partner responses suggested an acceptance of 
sexual life changes and persistence of the partner’s interest and desire, which were 
helpful in adapting and living with the disruption of cancer (Ussher et al., 2015).  
Open communication is one area that research focuses on to analyze emotional 
intimacy. Perz and colleagues position communication as critical to the acceptance of 
various fulfilling sexual and intimate practices after cancer (Perz et al., 2013).  Hawkins 
and colleagues also discovered that negative changes in sexual function were related to a 
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reduction in open communication (Hawkins et al., 2009). Similarly, others suggest that 
higher levels of sexual function were associated with higher levels of sexual open 
communication (Perz, Ussher, & Gilbert, 2014). In one study, many women reported 
communication issues, but 7.2% reported an increase in communication (Ussher et al., 
2012). Perhaps this was in an attempt to bolster emotional intimacy when sexual intimacy 
was lacking.  
Reis and Shaver proposed a model of intimacy based on the interpersonal process 
(Reis & Shaver, 1988). This model defines intimacy as a process in which individuals 
share important and self-relevant thoughts and feelings to another person, and as a result 
of the other’s reaction, feels that they are understood and appreciated (Reis & Shaver, 
1988).  This model highlights two key intimate interpersonal actions – self-disclosure and 
partner responsiveness (S. Manne & Badr, 2008). Manne and Badr evaluated this model 
for couples where the woman was undergoing breast cancer treatment (S. Manne & Badr, 
2008). The couples participated in discussions then subsequently rated four elements of 
communication: perceived self-disclosure, partner disclosure, partner responsiveness, and 
intimacy experienced. Interestingly, their results supported the model by Reis and Shaver 
only for the partner’s self-disclosure; the partner’s self-disclosure was a more important 
determinant of perceived closeness and emotional intimacy than the patient’s self-
disclosure (S. Manne & Badr, 2008).  This finding suggests that a patient’s self-
disclosure plays a lesser role in maintaining emotional intimacy, while that of the 
partner’s plays a bigger role (S. Manne & Badr, 2008). The group also observed that a 
partner’s response, especially self-disclosure, plays a role in patient distress (S. Manne & 
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Badr, 2008). In this vein, analyzing emotional intimacy and closeness should include 
evaluation of the intimate partner’s thoughts and feelings. Furthermore, due to the 
interpersonal nature many changes associated with breast cancer treatment (sexual 
dysfunction, body image, sexual self-concept, and relationship changes), the majority of 
aforementioned study findings highlight the importance of assisting couples, not just 
patients, to manage the difficulties associated with adjusting to life after breast cancer and 
its treatment. Clinicians and psychotherapists should take into account (and recognize the 
importance of) the partner and the relationship in order to best remedy any emotional 
intimacy issues caused by breast cancer management and its impact on sexuality and 
sexual life. 
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IMPACT OF TREATMENT ON THE INTIMATE PARTNER 
 
 
Little research on breast cancer focuses on the unique experience of the intimate 
partner. However, because intimate relationships are so important to partnered women 
during and after cancer treatment, delving deeper into the impact of relationship changes 
experienced by the intimate partner could shed light on how to bolster already strong 
relationships and correct struggling ones for the benefit of both partners and the patient in 
particular. In a study by Ussher and colleagues, 1348 participants answered a question on 
whether their partner experienced any negative consequences due to their breast cancer 
(Ussher et al., 2012). The most common reports were fear of hurting the partner during 
sex (52%), lack of interest in sex (37%), difficulties in communication (34%), tiredness 
(28%), change in role (seeing partner as a patient, 20%) (Ussher et al., 2012). In one early 
study, Wellisch and colleagues reported spouses had sleep, eating, and work 
disturbances, all attributed to their wives’ breast cancer (Wellisch, Jamison, & Pasnau, 
1978). Spouses reported feelings of being helpless, fearful, and sad (E. Zahlis & Shands, 
1991). Spouses also reported finding it hard to watch their wives struggle (E. Zahlis & 
Shands, 1991). A few men found breast surgery and the disfigurement of the breasts 
shocking, while others thought it was “not a big deal” (E. Zahlis & Shands, 1991). While 
there are parallels between the partner and patient’s feelings, there are experiences unique 
to the partner. Addressing the unique experiences of the partner is not meant to take away 
the focus from the BC patient or survivor. It is addressed, rather, because the 
relationships is an important support system for the patient and survivor. If certain areas 
of distress for the partner are pinpointed they can be addressed early by clinicians and 
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therapists in order to maintain a strong relationship for both partners. While the patient 
and partner do experience similar types of distress and fears, the two should not be 
equated. This section of the paper addresses some unique stressors for the intimate 
partner in three areas: emotional distress, role changes, and a disordered state of 
communication.  
 
Emotional Distress 
 
Emotional distress is not unique to the intimate partner, but each individual’s 
experience of this distress is. Significant emotional distress is observed in some husbands 
of women with breast cancer (Walker, 1997). In a recent study, Kauffman et al. (2016) 
found that patients and their partners were equally as likely to feel unsupported by their 
partner, feel down, or depressed (Kauffmann et al., 2016). In a well-known longitudinal 
study, Northouse and Swain showed that the spouse’s distress level was comparable to 
the level of morbidity in their wives (Northouse & Swain, 1987). Research consistently 
reports the fear of recurrence of the breast cancer being one of the main emotional 
stressors when the woman is in survivorship (Walker, 1997). Some men worried about 
what the future might bring and their wives’ survival (E. Zahlis & Shands, 1991). There 
is also greater fear of reoccurrence in male spouses with younger breast cancer surviving 
wives (Walker, 1997). In this particular study, when the emotional distress was elevated 
in one partner, the fear of recurrence score was only elevated in the partner in two cases, 
suggesting there is somewhat of an emotional compensation in the other partner (Walker, 
1997). Segrin and Badger found conflicting evidence for emotional compensation (Segrin 
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& Badger, 2014). They found that breast cancer survivors’ psychological and physical 
distress is significantly negatively affected by their partners’ stress, and vice versa 
(Segrin & Badger, 2014). Emotional stress also came from relationship changes. For 
some men, breast cancer treatment magnified already existing problems in the 
relationship (E. H. Zahlis & Lewis, 2010).  
 
Disordered State of Communication 
 
Communication can sometimes be lessened or disordered in the aftermath of 
breast cancer (Hawkins et al., 2009; Ussher et al., 2012). In a study by Ussher and 
colleagues, 7.2% of women described an upsurge in communication, however (Ussher et 
al., 2012). Studies have reported that male partners of women with breast cancer and 
survivors avoid discussing their worries with their partner in order to prevent adding to 
her distress (Sabo, Brown, & MS, 1986; Walker, 1997). Research also suggests that 
membership (past or present) in a support group was associated with more 
communication by women with breast cancer and to their male spouses’ greater 
satisfaction with that communication (Walker, 1997). It is unclear whether 
communication initiated by the partner or the patient is more beneficial to the 
relationship, but research does show that open communication is associated with greater 
intimacy (Hawkins et al., 2009). Regardless of where the deficit in communication lies, 
this disordered state of communication poses a unique stress on the intimate partner, such 
that they may not want to share concerns for fear of upsetting their partner or may not 
have the words to do so.  
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Role Changes 
 
Along with breast cancer and its treatment, there can come a change of roles 
within the couple. It is likely the spouse will provide the main practical caregiving. Due 
to the cancer and treatment, the spouse must now provide emotional and practical support 
at a new, higher level. Hilton, Crawford, and Tarko found two main foci reported by 
males coping with their wives’ breast cancer and chemotherapy: focusing on the wife’s 
cancer and care and focusing on the family in order to keep life moving forward (Hilton, 
Crawford, & Tarko, 2000). Spouses in a study by Zahlis and Shands talked about doing 
more child care, changing work schedules, and assuming the management of the 
household (E. Zahlis & Shands, 1991). In one study, expectations from male gender roles 
guided husbands' attempts to provide emotional support to their wives that was 
complicated by their understanding of their inability to meet all of their wives' needs 
(Samms, 1999). Some men also expressed feeling guilty because they could not help their 
partner more and were critical of their own capability of supporting her (E. Zahlis & 
Shands, 1991). These studies show role changes for only straight, male partners of breast 
cancer patients and survivors. Further research needs to be done on LGBT couples with 
one partner suffering with breast cancer in order to gain a well-rounded view of how 
gender roles and expectations impact the intimate partner and role changes after breast 
cancer.  
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THE BENFITS OF A SUPPORTIVE PARTNER 
 
AND CLOSE RELATIONSHIP 
 
 
Historically, research has centered around the psychological and emotional impact 
of caregiving on spouses and the impact of cancer on the general quality of the partnered 
relationship (S. Manne & Badr, 2008). Unfortunately, much of this research neglects the 
couple-level perspective; cancer is something that affects the couple, and appreciating 
this couple-level perspective may be a more useful approach for theoretical and clinical 
purposes (S. Manne & Badr, 2008). Research shows that partners in fulfilling 
relationships are conscious of vital functions of their relationship, make purposeful 
efforts to maintain those in hard times, and try to find opportunities to improve their 
relationship (S. Manne & Badr, 2008). In that regard, cancer can provide an opportunity 
for couples to forge a stronger intimate bond (S. Manne & Badr, 2008). Breast cancer and 
its management, leading to sexual dysfunction and psychological issues surrounding sex, 
could be problematic for increasing intimacy sexually. However, Manne and Badr 
suggest a focus on bolstering closeness and adapting to cancer in order to increase 
relationship intimacy (S. Manne & Badr, 2008). 
Manne and Badr (2008) designed an intervention for couples dealing with cancer 
that centered around communication behaviors. The model proposed that patients and 
their partners participate in behaviors that either promote or undermine the closeness 
level in their relationship and that the closeness of the relationship is an important 
determinant of patient and partner’s psychological adaptation to the experience of cancer 
(S. Manne & Badr, 2008). They created a model with three processes, collectively called 
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the “Relationship Intimacy Model”. The three processes include reciprocal self-
disclosure, partner responsiveness (feeling understood, cared for, and accepted by the 
partner), and relationship engagement (S. Manne & Badr, 2008). Their study surveyed 25 
couples that completed 5 sessions with the designed intimacy-enhancing intervention, 
and the results suggest that the model improved patient and partner perceptions of the 
closeness level in their relationship and reduced both partner’s distress (S. Manne & 
Badr, 2008). The results suggest that a close relationship, and most likely a supportive 
and involved partner, can reduce the distress caused by cancer and its management.  
Much research supports this claim. A recent study by Borstelmann and colleagues 
(2015) found that younger women (mean age 35.4 years) with breast cancer and those in 
un-partnered relationships had more anxiety than women in supportive partner 
relationships. These findings suggest that partner support plays a role in a young 
woman’s adjustment to breast cancer, where the supportive efforts by the partner could 
potentially protect against the impact of stress (Borstelmann et al., 2015). In a study by 
Winch and colleagues, a supportive partner was found to be instrumental in helping 
women overcome sexual issues caused by lymphedema, a common side effect of BC 
treatment, and body image concerns (Winch et al., 2015). Wilmoth found that women 
with strong intimate relationships adjusted more successfully to the sexual side effects of 
breast cancer treatment and the subsequent “altered sexual self” (Wilmoth, 2001). 
Interestingly, one study found that a woman’s perception of her spouse’s support can be 
just as significant as obvious demonstrations of that support (Wimberly et al., 2005).  
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As much as a supportive partner has been found beneficial, a non-supportive 
partner can be detrimental. Multiple studies have found that a non-supportive partner can 
create harmful disease outcomes and poor psychological and practical adjustment to 
breast cancer  (Chekryn, 1984; Northouse, Dorris, & Charron-Moore, 1995; Peters-
Golden, 1982; Nancy Pistrang & Barker, 1992). It has also been found that the partner’s 
support is of such significance that good support from family and friends does not make 
up for insufficient spousal support (Coyne & DeLongis, 1986; N. Pistrang & Barker, 
1995). Older women (greater than 60 years of age) in difficult, non-supportive partnered 
relationships, seem to find alternative ways to cope (Sawin, 2012). This finding provides 
further evidence than older women can cope and deal more effectively with illness, 
perhaps because they are dealing with other issues related to age and have a wide breadth 
of life skills and experiences (Crooks, 2001; De & A, 1999; Sawin, 2012).   
Because spousal support has been found to be so beneficial for women with breast 
cancer and survivors to adapt psychologically, researchers sought to investigate what 
kind of support is perceived as the most helpful. Women often perceive their partners as 
better supporting instrumentally rather than emotionally, but open communication with 
the acknowledgement of the cancer and sharing deep feelings with a sensitivity to the 
partner’s present needs and feelings have been found to aide adaptation to breast cancer 
(Holmberg, Scott, Alexy, & Fife, 2001; S. L. Manne & Zautra, 1989; Skerrett, 1998).  
Practicing reciprocal self-disclosure and being emotionally involved and empathetic seem 
to be partner actions that are beneficial for a women adjusting to cancer (Holmberg et al., 
2001; Manne et al., 2006; N. Pistrang & Barker, 1995; Zunkel, 2003). 
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The following personal interviews show two breast cancer survivors currently in 
their mid-fifties sharing experiences of their journey and battle with breast cancer. Both 
women mention intimate and personal details of their partner relationships, and both 
women acknowledge the importance of having a supportive partner and strong, healthy 
relationship. The interviews underscore some of the negative effects of BC treatment on 
sexual function and sexual identity and emphasize the importance of a supportive 
intimate relationship to alleviate and protect against some of the stressors due to those 
sexual issues.  
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SURVIVOR INTERVIEWS: LIFE AFTER BREAST CANCER  
 
 
The following interviews were conducted in person over the course of two hours 
and one hour, respectively, at local cafes. Each survivor’s story is different. Each woman 
had a unique experience and different effects on their sexual lives and relationships. 
However, both women did experience changes in sexual function, self-esteem, and their 
partner relationship due to breast cancer treatment. Both women also had strong partner 
relationships and supportive intimate partners and mentioned that this played an 
extremely important role in their survivorship. The women both mentioned that cancer 
likely strengthened their relationship and brought them closer together. For these women, 
cancer was an opportunity to strengthen an already strong bond with their spouse.  
 
Survivor Interview 1 
 
Pitingolo, Cathy. Personal interview. 12 December 2016.  
Interviewee: Carla* name changed for anonymity   
Interviewer: Nicolina Mascia 
Date and Time: December 12, 2016, 7:00pm 
Location: Panera Bread (Gillette, New Jersey) 
 
Background  
1.! When were you diagnosed with BC and at what age?  
I was 41, and the date was July 1, 2004. 
2.!  What type of cancer did you have?  
 51 
I brought my little paper because I can never remember. It was invasive lobular 
breast cancer. It was a 5.2 cm tumor, with 8+ affected nodes, ER and PR positive, 
HER2 negative. 
3.!  What stage were you diagnosed with?  
I was diagnosed with (stage) 3+.  
4.! How was the cancer detected? Breast self exam, clinical exam, mammogram 
Let’s see. I have to go by the months. So it was May. I had my normal 
gynecologist apt. She said I had a clump of fibroids. I didn’t even know; I didn’t 
feel it. I had a normal mammogram done 6 months prior and that was clear. Then 
I was showing everybody, and I kept rubbing it. So then it started to hurt. So I 
went back to my gynecologist, and she had me do a diagnostic mammogram. That 
was mid June. Then she sent me to the breast surgeon for the diagnosis.  
5.! Do you have a family history of breast cancer?  
Sort of. My mother died of ovarian cancer. Her mother (my grandmother) and 
sister (my great aunt) died of breast cancer. 
6.! What were your top three biggest fears?   
Well, the first, the biggest one was if I was going to live or die. I had four children 
under the age of nine - 3 four-year-old triplets and 1 eight-year-old.  
7.! What was your treatment process? Chemo, radiation, surgery, or a 
combination? 
So I had surgery first, and I had a double mastectomy and a TRAM flap 
reconstruction in the same surgery. Then I had the chemo. I did ATC is what it 
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was called. Adriamycin, Cytoxan, and Taxol - ATC. I was also in a clinical study. 
So I think usually you get the doses of AC once a month for three months, but I 
got a half dose every other week for 6 weeks. I also got Taxol weekly for four 
months. Then I had the radiation which started in March. I had 25 rounds, and 
finished in mid-April. I always remember when I finished radiation because it was 
a week before my husband’s father died.  
Breast Surgery 
1.! Was this type of surgery the best option for your cancer?   
For sure. I had the option of doing one breast but decided to do both because of 
my family history. I also could have gone with implants. A bunch of people I 
know did the implants, but I’m the only one that went with the TRAM flap. I had 
enough to work with so that worked for me. She didn’t recommend a lumpectomy 
(probably because of lymph nodes). 
2! Would you go through this type of surgery again?  
Yes, absolutely.  
My plastic surgeon was just someone who came into my life and then left. She 
was amazing. She wanted me to have nipple reconstruction and the tattoo to make 
me “whole”. She was so much into making people “whole” again. I know a lot of 
people that never did tattooing or nipple reconstruction. And I guess you just kind 
of get used to looking the way you do. Now my tattoo is faded the nipple is 
flattened, which I think is due to weight loss and gain over the years. But I’m glad 
I did it because she tried to give me the whole picture, my whole body. 
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1.! Was your reconstructive surgery done at the same time as the mastectomy or 
as a separate surgery? 
It was done at the same time. I think I was in surgery for 7 hours. Then I spent 
four days in the hospital. I was so hunched over until the skin stretched, and I had 
4 drains down to my hips. I got lucky and had great nurses that took great care of 
me. I was in pain for about two weeks. I was wearing everything from my 
husband’s closet - his underwear, shirts, you know because they were all bigger. 
I’d walk outside to get a little sun, and I was walking like I was 100 years old, so 
slowly. The pain was pretty bad for two weeks. I had a C-section, and it was 
worse than that. I actually think that pain kind of prepared me for it.  
2.! How long after surgery until you felt like yourself?  
Six weeks almost to the day. They told me it would be 6-8 weeks to feel normal 
again, and I remember it so vividly it was 6 weeks exactly when I started to feel 
like me again.  
3.! Were you happy with the aesthetic outcome of the reconstructive surgery (on 
a level of 1 to 10, 10 being extremely happy)? 
Very happy, after the surgery it was a 10/10. After having just chemo, it was still 
a 10. After radiation, it was like an 8 because it shrunk the one breast smaller. 
4.! Did you feel as self-confident following reconstruction as before breast 
cancer? 
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Actually probably more! I was thinner. When I had my triplets I had right breast 
calcification, and they took a chunk of my breast when removing it. After the 
reconstruction, it was fixed! 
5.! Did you have any complications post-surgery or long-term complications?  
I had a little bit of necrosis in the left breast, where tumor was. It happened within 
2 months of surgery, and they think it was the tail of the flap. But we left it. I also 
had stitches around the left nipple that didn’t heal so they had to re-stitch those.    
Sexuality 
1.! Did you notice any changes in sexual function and sexual well-being 
following the diagnosis and treatment?  
Definitely. One of the things they don’t tell you when you have this type of 
surgery is that you lose all feeling. All that great feeling is now gone; I have no 
feeling in my breasts. And that was a huge bummer! I was like - well now what 
do I do? I also had no desire. Most of the time I wasn’t in the mood, and when I 
wanted to be in the mood, I couldn’t be. I was missing all those cues from my 
breasts. Sex was also uncomfortable and a little painful.  
2.! Did you experience any anxiety about these issues? 
I tried to pretend those issues weren’t there so we could be intimate, to keep my 
husband happy. So yes, that was stressful.  
3.! If you did notice changes in sexual functioning, how did this affect your 
relationship with your partner?  
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It did. When we did go through those dry spells it definitely made things more 
tense.  But you tried to alleviate it any way you could. It was stressful, and 
because of the lost feeling, my body didn’t give me those cues. I had the 
premature menopause symptoms, which made sex uncomfortable, and I couldn’t 
take any medications for that because they mostly all have estrogen and would 
have reacted with my cancer since I’m estrogen receptor positive. So you’re stuck 
trying to figure it out.  The intimacy level now though is just completely different. 
I think it’s more due to the cancer rather than to age.  
4.! What was the attitude of you and your partner to the sex issues following 
diagnosis and treatment? How important were the sexual issues to you and to 
your partner? 
I’d say it was more important for my husband. After kids, I was kind of on the 
down swing of sex anyway. And we’re never alone anyway. But it’s 
disappointing. It should be easier, unplanned, and unthought-of, but it’s not. The 
desire is so much less.  
5.! How did sexuality and sex life changes influence your quality of life? 
I’d say it sometimes did, still does. When we aren’t intimate for a while, there’s 
more tension. Until I give in, and then we’re good (laughs).  
6.! Have you sought out or received professional counseling for issues with 
sexuality? If so, please describe.  
No, I really just dealt with it. My husband might not have gone. Though, he 
would probably go if I begged to. I’m just thinking of that movie - Meet the 
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Fockers. Where Barbra Streisand was the sex therapist. We need that for women. 
Someone who is just carefree and non-judgmental. They don’t really talk about 
these issues when you go to the oncologist or the breast surgeon.  
7.! Have you sought out or received care from a physician for sexual issues? If 
so, please describe. 
My gynecologist tried to help with all sorts of remedies. She was a female doctor. 
My oncologist was an older gay man and talking to him was a little different. He’s 
the one that told me I couldn’t take anything with estrogen because it would react 
with the tumor.  
Body Image 
1.! How did the changes in sexuality affect your self-esteem and body image?  
My self esteem actually didn’t change that much due to it. 
2.! How did the effects of breast cancer treatment affect your self-esteem and 
body image?  
I think about 2 months into chemo was when it started to go down. All my hair 
was gone. I spent a lot of money on this beautiful wig - something I’d never do 
again. I was feeling so blah and was swollen because of the steroids. I had no 
eyelashes, no eyebrows. I have yellowish skin to begin with, and I was so 
green/yellow with the chemo. That’s when I felt the most self-conscious. But I 
just kind of kept going. I was always on the go with my kids making sure they 
were taken everywhere they needed to go. I wore the wig for only about three 
months then I went around with scarves and bandanas that my kids bought me. 
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When I started the taxol my hair started growing back, and I’d say it’s thicker 
now than pre-cancer. My kids kept me going.  
3.! Did you experience any anxiety about the changes in your body due to 
treatment? 
No really. I had preschool aged kids so I kept going. 
4.! Did you make any changes in wardrobe post mastectomy?  
 Nope. Not that I can think of.  
Support System 
1.! What was your most important support system? 
My girlfriends in town. They made sure we had dinner every night, took the kids 
places. They really went above and beyond to help out. I have 4 sisters and 2 
brothers that were important. They were there for me as family, but I really have 
to give my friends in town more credit.  
2.! Was spirituality and/or faith important at any point or throughout your 
journey?  
Oh, all the time. Even now. I’m always a little fearful it could come back.   
Partner 
1.! How did you perceive your breast cancer affecting your spouse/partner?  
I’d say he was mostly frightened. He’s still frightened about it coming back.  
But for the most part it’s behind us. We couldn’t let it control our lives.  
2.! Were you satisfied overall with your relationship post-treatment for breast 
cancer? 
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Yes. Hey, I’m still married to him.  
3.! Were you satisfied with your sexual intimacy? Not really. I had no desire, and 
when I made the effort, it was very uncomfortable.#
4.! Were you satisfied with your emotional intimacy? #
I’d say so. It probably brought us closer together. It really didn’t cause any 
relationship stress. I think my husband maybe appreciated life more or life with 
me more. 
5.! Did you have open communication with your partner? If so, how important 
was communication in your relationship  
More communication – when one is stressed out you balance the other out. 
6.! If you did have a supportive partner, do you think this played an important 
role in your fight with cancer? Please explain.  
Absolutely. It was hugely important. Things can’t remain as they were while 
you’re dealing with breast cancer. They could be the same eventually, but not 
while you’re going through it. My husband’s father was also dying at the same 
time so I’d say I was a big support for him.  
Wrap Up 
1.! What advice would you give to someone newly diagnosed with breast cancer? 
Firstly, that you could lose feeling in your breasts. That’s important and 
something no one told me. I guess it really depends on the type of surgery though. 
If I meet someone who’s having the same surgery as I had, I’d tell them to get a 
lift chair. I couldn’t really lie down or sit up because of the pain. So I had a chair 
 59 
that could tilt and lie me down and sit me back up. It helped so much. Also, the 
wig thing. Don’t spend a lot of money because you don’t really need to. Well, you 
need it to get started for the self-esteem, but eventually, it becomes easier. Also, 
take all the help you can get. Don’t think you can do it all on your own, because 
you can’t.  
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Survivor Interview 2 
 
Tumolo-Decuollo, Jeannette. Personal interview. 1 December 2016.  
 
Interviewee: Jeannette Tumolo-Decuollo  
Interviewer: Nicolina Mascia 
Date and Time: December 1, 2016, 3:00pm 
Location: Hunterdon Medical Center (Flemington, NJ) 
 
Background  
1.! When were you diagnosed with BC and at what age?  
I was 47 years old.  
2.! What type of cancer did you have?  
I had stage 2 ductal carcinoma.  
3.! How was the cancer detected? Breast self exam, clinical exam, mammogram 
I felt a lump the size of a tennis ball, and went to my gynecologist for a 
mammogram.  
4.! Do you have a family history of breast cancer? No, I don’t.  
5.! What was your biggest fear?   
Really the biggest one was losing my life.  
6.! What was your treatment process? Chemo, radiation, surgery, or a 
combination 
I had 7 lumpectomies in 6 years in order to get clean margins. I also had oral 
chemo for 6 years.  
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Breast Surgery  
1.! If you had breast surgery, what kind of surgery did you undergo?  
I had 7 different lumpectomies over 6 years.  
2.! Was this type of surgery the best option for your cancer?  
This was the only type my surgeon recommended for me.  
3.! Would you go through this type of surgery again?  
Absolutely. It was a long road for those 6 years, but I would fight again if I had 
to.  
4.! Was your reconstructive surgery done at the same time as the mastectomy or 
as a separate surgery? I didn’t have a need for reconstruction, luckily.  
5.! Were you happy with the aesthetic outcome of the breast surgeries? I wasn’t 
unhappy; I just got used to them. 
6.! Did you feel as self-confident following the surgeries as before breast cancer? 
I didn’t have many self-confidence issues at all.  
Sexuality 
1.! Did you notice any changes in sexual function and sexual well-being 
following the diagnosis and treatment?   
Other than sex taking a backseat for those years, I did not see much change in 
sexual function or sexual behavior. I can remember it was little uncomfortable for 
me for a few years, which subsided.  
2.! Did you experience any anxiety about these issues? 
I was lucky to have support that I didn’t need to be anxious about it.  
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3.! If you did notice changes in sexual functioning, how did this affect your 
relationship with your partner?   
None of the issues had any effect on our relationship. He was with me 100% of 
the way, and although sex occurred less often, it was still a good sexual 
relationship.  
4.! What was the attitude of you and your partner to the sex issues following 
diagnosis and treatment? How important were the sexual issues to you and to 
your partner? 
Like I said, he was with me 100%, and sex just took a backseat in our lives for a 
bit. It really wasn’t an issue.  
5.! How did sexuality and sex life changes influence your quality of life? 
I guess it did only slightly though. I’m not sure it was “worse” quality of life in 
that area, just different. It became a different relationship altogether, and still is. 
In the grand scheme of our lives, sex just isn’t a worry for us.  
6.! Have you sought out or received professional counseling for issues with 
sexuality? If so, please describe.  
I didn’t have a need to.  
7.! Have you sought out or received care from a physician for sexual issues? If 
so, please describe.  
I didn’t have a need for that either.  
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Body Image 
1.! How did the changes in sexuality after breast cancer treatment affect your 
self-esteem and body image?  
To be 100% honest, I had only a few self-esteem or body image issues. I was 
happy with my body before and after cancer, but it did take a while to get used to 
the new look, especially since I had 7 different surgeries and each result was a 
little different. I felt a little like I lost a part of my feminine nature for a while.  
2.! Did you make any changes in wardrobe post mastectomy?  
Not at all. I wore the same things. Maybe I stayed away from the super low cut 
stuff, but I wasn’t wearing that stuff at my age anyway.  
Support System 
1.! What was your most important support system?  
My faith and my husband. He was 100% supportive.  
2.! Was spirituality and/or faith important at any point or throughout your 
journey?  
Faith was very important throughout the entire time. I grew up Catholic, and faith 
was important to me as a young child, teenager, and is important even now.  
Intimate Partner  
1.! How did you perceive your breast cancer affecting your spouse/partner?  
He was certainly scared. Definitely worried often, especially about it returning.  
2.! Were you satisfied overall with your relationship post-treatment for breast 
cancer? 
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Absolutely! He really was great throughout the whole process. And it was 6 years 
of it. 
3.! Were you satisfied with your sexual intimacy? 
Sex has never really been an issue for me. I’ve always liked it, and even though it 
doesn’t happen as often, I was lucky enough to still enjoy it after treatment.   
4.! Were you satisfied with your emotional intimacy?  
Very- I think we grew closer as a result of the cancer. We had to be strong for 
each other to make it.  
5.! Did you have open communication with your partner? If so, how important 
was communication in your relationship  
Definitely – it was very important to us. We were very honest about our feelings.  
6.! If you did have a supportive partner, do you think this played an important 
role in your fight with cancer? Please explain.  
I think it played a huge role in getting through things. It’s hard to explain, but it 
tests your relationship in a big way. If you get through it together, you can do 
anything.  
Wrap-Up 
1.! What advice would you give to someone newly diagnosed with breast cancer? 
It would definitely be to (1) listen to your doctor, and (2) ask tons of questions! 
No question is a stupid question.  
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DISCUSSION 
 
Fortunately, more and more women are surviving breast cancer. With an increase 
in survival rates, there should be a shift to bolstering quality of life for these survivors. 
The findings presented in this paper confirm the many struggles related to sexual changes 
due to breast cancer treatment physically, psychologically, and interpersonally that can 
decrease quality of life overall. They highlight the importance of health professionals and 
support workers recognizing these sexual changes when delivering health education and 
when developing helpful interventions. Without further studies, it is difficult to determine 
the interaction of physical sexual dysfunction, psychological issues, and relationship 
issues due to sexual changes after breast cancer treatment. However, the three areas seem 
to be interconnected in some way. It seems that when examining sexuality after breast 
cancer treatment, a woman’s body cannot be dealt with apart from her sexual self-concept 
and self-image in relation to her intimate partner and society. These factors together are 
important for living sexually after breast cancer. Therefore, it is important that clinicians 
approach sexuality from an interdisciplinary standpoint and take into account the 
physical, psychological, and interpersonal aspects of sexual changes due to breast cancer 
treatment. It should then stand that psychological interventions intended to reduce stress 
and improve quality of life after cancer treatment should incorporate elements on sexual 
health. Likewise, sexual interventions should integrate psychological and interpersonal 
components. Living beyond breast cancer is not solely about physical sexual interactions, 
sexual self-concept, or intimate relationships but rather a balance of satisfaction in all 
 66 
three areas. In addition, the intimate partner’s unique experience should not be neglected, 
as he or she plays an extremely important role in the woman’s experience with breast 
cancer and can help the woman to cope with these physical, emotional, and relational 
sexual changes.  
 
The Value of Studying Sexuality 
There is a long-standing misconception that because women with breast cancer 
and survivors are usually past middle age, possibly into menopause, they are no longer 
interested in sexuality or intimacy. While research has shown that younger women 
needing breast surgery opt for immediate breast reconstruction, meaning they might care 
more about sexuality, body image, or sexual life, this does not mean the older women 
have no concerns about sexuality. Women no longer interested in intercourse can find 
alternate ways to achieve intimacy, but that should not mean researchers stop looking into 
sexual dysfunction for the women that are negatively effected. Sexuality is still important 
for the quality of life of many women who struggle with breast cancer, especially since 
many of the sexual problems have to do with the intimate partner and the relationship. 
Distress can come from tension in the relationship due to problems with sexuality and 
intimacy, further lowering the quality of life for women with breast cancer and survivors. 
On the positive side, a supportive partner and strong relationship has been shown to help 
women cope. Likewise, some research shows the positive effect of breast cancer and 
treatment bringing the couple closer together. However, this should not validate 
neglecting research on how sexual side effects of treatment negatively affect couples. 
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Since it is unclear what exact factors predict if a couple will grow closer or have tension, 
it does not make sense to ignore sexuality in the conversation for all couples dealing with 
breast cancer, regardless of stage of disease, treatment status, age, race, and sexual 
orientation.  
 
What Is a “Supportive” Relationship? 
From the data presented in this paper, it appears that a strong, healthy relationship 
and a supportive intimate partner could alleviate some of the sexual health stressors due 
to breast cancer and help the woman to cope. However, the definition of a “good” 
relationship is different each individual and couple. What works for one couple does not 
necessarily work for a different couple. This is especially true in regards to sexuality, 
which has different meanings for each individual. In healthy relationships, each couple 
develops methods of communication, caring, and supporting in ways that best fit each 
individual in the couple. It seems that in order for a breast cancer patient or survivor to 
benefit from a strong, supportive relationship, she must be satisfied with the status and 
strength of that relationship. There are objective criteria for a good, healthy relationship 
that could make it difficult to find which specific factors are more likely to help the 
woman with breast cancer cope, but it is still possible to see the benefits of a supportive, 
healthy relationship, as long as the woman herself is satisfied with the relationship status.  
While this paper’s focus is on the sexuality and intimacy effects of breast cancer 
treatment in partnered relationships, the single women suffering with intimacy issues due 
to BC should not be neglected.  
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Clinically Approaching Sexual Function 
Sexual dysfunction and issues with sexual health are a reality for many women 
who have have undergone breast cancer treatment. It is important to include issues of 
quality of life, such as sexual health, in plans for the management of breast cancer and 
beyond into survival (Boswell & Dizon, 2015). However, the effects of breast cancer on 
sexuality are not usually discussed by clinicians, in patient care plans, or in patient 
education. Unfortunately, while there is an availability of treatments (whether effective or 
not) for sexual dysfunctions and identity issues, there is a disconnect between self-
reported need for professional help and actually receiving the care (Kedde et al., 2013). 
Health care professionals often do not mention sexual problems due to time constraints, 
embarrassment, or lack of knowledge or experience (Kedde et al., 2013). Patients will 
often forgo bringing up similar topics perhaps due to feeling embarrassed or 
uncomfortable. Research does suggest that women who sought information about sexual 
side effects of breast cancer treatment had a more successful adjustment to sexual 
changes, yet women are still not seeking or receiving information (Wilmoth, 2001). 
Perhaps most concerning is that due to a lack of understanding or resources along with 
the distress of cancer treatment, sexual experiences and intimacy can be sidelined at a 
time when sexuality could be quite helpful.  
Discussing sex and sexuality requires strong patient-doctor connections with open 
communication and medical understanding. If physicians ask questions about sexual 
health in their routine questioning, patients may feel at ease and open up about issues 
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they are facing. Park, Norris, and Bober published a model of communication for patients 
with cancer based on five A’s – Ask, Advise, Assess, Assist, and Arrange (Park, Norris, 
& Bober, 2009). Importantly, the group suggests that these issues are tackled in an 
interdisciplinary manner rather than by a single health care provider (Park et al., 2009).  
Addressing sexual function after breast cancer treatment includes delving into a 
patient’s history and understanding active medical problems and current medications, as 
many sexual dysfunctions arise from medications, such as beta-blockers, and 
comorbidities, such as diabetes mellitus (Perez, Gadgil, & Dizon, 2009). It also requires 
delving into areas of intimacy and sexuality that can be hard to explain or demonstrate, 
since sexuality and sexual expression are different for each individual.  
It is important to note that intimacy can be defined as emotional closeness, even 
in the absence of sexual activity. Perz and colleagues questioned patients, their partners, 
and their health care providers (Perz et al., 2013). The group found that clinicians view 
sexual health most often as physical whereas patients and their partners emphasized 
emotional intimacy as important and highly valued, even in the absence of physical 
sexual relations (Perz et al., 2013). Perz and colleagues also found that even though 
physical sex may not be desired or possible after cancer, relationship satisfaction is 
attained through open communication and “non-genital intimacy” (Perz et al., 2013). 
Therefore, medical professionals should not only focus on physical sexual health but also 
on emotional intimacy and sexuality as it pertains to the couple. Moreover, due to the 
interpersonal nature many changes associated with breast cancer treatment (sexual 
dysfunction, body image, sexual self-concept, and relationship changes), clinicians 
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should support couples, not just patients, to manage the issues associated with sexual 
changes and to adjust to life after breast cancer treatment. Clinicians and psychotherapists 
should take into account the partner and the relationship in order to best remedy any 
emotional intimacy issues caused by breast cancer management and its impact on 
sexuality and sexual life. 
 
Further Research  
The literature lacks research conducted on the sexual experience for breast cancer 
survivors. Further investigation is needed into the lives of survivors five, ten, and twenty 
years after their breast cancer experience as more people are now surviving the disease. 
Much of the research done on intimate partners of women with breast cancer is similarly 
done in the early stages of treatment. Further research is needed on how the intimate 
partner is affected emotionally, psychologically, and interpersonally over the course of 
the disease and into survivorship.   
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